Seek Returns

AMGN vs. PCVX: Amgen vs. Vaxcyte Stock Comparison

How do Amgen (AMGN) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Amgen (AMGN) has more than two decades of public-market history since June 17, 1983, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Amgen (AMGN) and Vaxcyte (PCVX)
Profile ItemAMGNPCVX
NameAmgen Inc. Common StockVaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
PCVX
GSPC
Loading price history…
Amgen (AMGN) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Total Return (1Y)48.82%59.00%
Total Return (3Y, Annualized)24.31%11.29%
Total Return (5Y, Annualized)20.67%21.60%

Risk Profile

Drawdown History

AMGN
PCVX
GSPC
Loading price history…
Amgen (AMGN) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Volatility (1Y, Annualized)29.12%56.01%
Beta (5Y)0.431.26
Max Drawdown (5Y)-24.86%-76.22%
Avg. Volume (3M)2.76M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Sharpe Ratio (1Y)1.530.98
Sortino Ratio (1Y)2.361.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Amgen (AMGN) at 24.14% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Amgen (AMGN) at 35.79% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
ROE (TTM)78.35%-42.68%
ROA (TTM)8.91%-24.98%
Net Margin (TTM)24.14%0.00%
Operating Margin (TTM)35.79%0.00%
Gross Margin (TTM)72.47%0.00%

Growth

Revenue Growth

Only one side can be read here: Amgen (AMGN) reports revenue growth of 9.95%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Revenue Growth (YoY)9.95%--
Revenue Growth (3Y CAGR)11.77%--
EPS Growth (YoY)88.23%--
EPS Growth (3Y CAGR)5.52%--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Current Ratio (MRQ)1.484.56
Debt / Equity (MRQ)3.760.09
Net Debt / EBITDA2.31--

Dividends

Dividend Yield (TTM)

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Vaxcyte (PCVX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
Dividend Yield (TTM)2.16%0.00%
Dividend Payout Ratio (TTM)57.62%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Amgen (AMGN), whose P/S ratio of 6.40 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Vaxcyte (PCVX)
MetricAMGNPCVX
P/E Ratio (TTM)26.69--
P/S Ratio (TTM)6.40--
P/B Ratio (MRQ)17.353.83
Free Cash Flow Yield (TTM)2.96%-5.24%